Pharmaceutical Research and Development

Research writing moves between a notebook, a report and a submission without a clean boundary. A summary drafted by a model can travel the same path and lose its provenance on the way. Scientists want the help anyway. This starter keeps the traffic inspectable and pushes the weak answer back before it reaches a document.

Discovery and development teams work under good practice expectations and an electronic records rule. Both ask for attributable, legible and contemporaneous evidence. An assistant that drafts a protocol section or summarizes a study report enters that evidence chain. The question is whether the traffic can be described later with confidence.

This chain front loads its blocking controls. A prompt first meets injection screening, which protects the rules that follow from a planted instruction. The identity gate rejects a request with no verified caller. A health data stage adds record level matching to the general identifier sweep, and masking hides patient, member and policy numbers.

Response controls are not equal in force. Scoring demands 0.88 combined and treats relevance and accuracy as equal halves, at 0.78 and 0.80. A failure there blocks the answer by default. Source checking is softer, because a weak citation is flagged and the text still arrives. Neither control runs against a streamed response, so a streaming client loses both.

Two honest limits close the picture. The audit step marks an allow decision and does not create records, retention or an evidence archive that an inspector would accept. Human review is a configuration point with nothing in it, so no draft waits for a named approver today. Captured history holds metadata only, which keeps study text out of that record. Choose the Clinical Trials starter when the work centers on a regulated study document rather than discovery science.